Kyverna Therapeutics (KYTX) Enterprise Value (2024 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Enterprise Value data on file, last reported at -$233.0 million in Q1 2026.

• Quarterly Enterprise Value rose 3.98% year-over-year to -$233.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$233.0 million (up 3.98% YoY) and the FY2025 annual result came in at -$279.3 million, up 2.35% from the prior year.
• Enterprise Value advanced to -$233.0 million in Q1 2026, from -$279.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$23.0 million in Q3 2023 to a low of -$369.8 million in Q1 2024.
• A 4-year average of -$202.6 million and a median of -$233.0 million in 2026 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value sank 1300.11% — and 2025, when it surged 46.78%.
• Tracing KYTX's Enterprise Value over 4 years: stood at -$57.5 million in 2023, then plunged by 396.98% to -$286.0 million in 2024, then rose by 2.35% to -$279.3 million in 2025, then increased by 16.56% to -$233.0 million in 2026.
• The last three Enterprise Value figures came in at -$233.0 million (Q1 2026), -$279.3 million (Q4 2025), and -$171.1 million (Q3 2025), per Business Quant data.